Safety and efficacy of parsaclisib in combination with rituximab, bendamustine + rituximab, or ibrutinib in patients with previously treated B-cell lymphoma : analysis of a phase 1 dose-finding study (CITADEL-112)
Sancho, Juan-Manuel (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Abrisqueta, Pau (Vall d'Hebron Institut d'Oncologia)
Kumar, Abhijeet (University of Arizona)
Cordoba, Raul (Hospital Universitario Fundación Jiménez Díaz)
Tani, Mónica (Santa Maria delle Croci Hospital (Itàlia))
Langmuir, Peter (Incyte Corporation (Estats Units d'Amèrica))
Rappold, Erica (Incyte Corporation (Estats Units d'Amèrica))
Liu, Teng (Incyte Corporation (Estats Units d'Amèrica))
Lopez-Guillermo, Armando (Hospital Clínic i Provincial de Barcelona)

Date:	2024
Abstract:	Parsaclisib, a potent and highly selective phosphoinositide 3-kinase δ inhibitor, has shown clinical activity in relapsed/refractory (R/R) B-cell lymphoma. The phase 1 CITADEL-112 (NCT03424122) study assessed safety and efficacy of parsaclisib in combination with investigator choice standard of care (SOC; rituximab [Treatment A], rituximab plus bendamustine [Treatment B], or ibrutinib [Treatment C]) in 50 patients with R/R B-cell lymphoma. The most common treatment-emergent adverse events included neutropenia (62. 5%, 50. 0%, and 50. 0% of patients in Treatments A, B, and C, respectively); diarrhea (37. 5%) and anemia (31. 3%) in Treatment A; abdominal pain, asthenia, diarrhea, and nausea (each 33. 3%) in Treatment B; and increased alanine and aspartate aminotransferase (each 37. 5%) in Treatment C. Objective responses were observed in 13 patients (81. 3%) in Treatment A, 10 (55. 6%) in Treatment B, and 8 (50. 0%) in Treatment C. Parsaclisib combined with SOC therapies had an expected safety profile and promising efficacy in patients with R/R B-cell lymphomas.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Published in:	Leukemia and Lymphoma, Vol. 65 Núm. 7 (2024) , p. 911-921, ISSN 1029-2403

DOI: 10.1080/10428194.2024.2331626

11 p, 1.5 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Articles > Research articles
Articles > Published articles